Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta – Ken Research - PowerPoint PPT Presentation

About This Presentation
Title:

Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta – Ken Research

Description:

It plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. – PowerPoint PPT presentation

Number of Views:12
Slides: 9
Provided by: kenrsearch12
Category: Other
Tags:

less

Transcript and Presenter's Notes

Title: Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta – Ken Research


1
Inhibitor of Nuclear Factor Kappa B Kinase
Subunit Beta Ken Research
2
Inhibitor of Nuclear Factor Kappa B Kinase
Subunit Beta (Nuclear Factor NF Kappa B Inhibitor
Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC
2.7.11.10)- Inhibitor of nuclear factor kappa-B
kinase subunit beta is a protein encoded by the
IKBKB gene. It plays an essential role in the
NF-kappa-B signaling pathway which is activated
by multiple stimuli such as inflammatory
cytokines, bacterial or viral products, DNA
damages or other cellular stresses. It acts as
part of the canonical IKK complex in the
conventional pathway of NF-kappa-B activation and
phosphorylates inhibitors of NF-kappa-B on 2
critical serine residues. Free NF-kappa-B is
translocated into the nucleus and activates the
transcription of hundreds of genes involved in
immune response, growth control, or protection
against apoptosis. Inhibitor of Nuclear Factor
Kappa B Kinase Subunit Beta (Nuclear Factor NF
Kappa B Inhibitor Kinase Beta or I Kappa B Kinase
2 or IKBKB or EC 2.7.11.10) pipeline Target
constitutes close to 8 molecules. Out of which
approximately 6 molecules are developed by
companies and remaining by the universities/instit
utes. The molecules developed by companies in
Preclinical stages are 6 respectively. Similarly,
the universities portfolio in Preclinical and
Discovery stages comprises 1 and 1 molecules,
respectively.
3
Report covers products from therapy areas
Oncology, Immunology and Gastrointestinal which
include indications Glioblastoma Multiforme
(GBM), Inflammation, Acute Myelocytic Leukemia
(AML, Acute Myeloblastic Leukemia), Breast
Cancer, Colorectal Cancer, Inflammatory Bowel
Disease, Mantle Cell Lymphoma, Ovarian Cancer,
Pancreatic Cancer, Prostate Cancer, Rheumatoid
Arthritis, Solid Tumor and Squamous Cell
Carcinoma.The latest report Inhibitor of
Nuclear Factor Kappa B Kinase Subunit
Beta-Pipeline Review, H1 2018, outlays
comprehensive information on the Inhibitor of
Nuclear Factor Kappa B Kinase Subunit Beta
(Nuclear Factor NF Kappa B Inhibitor Kinase Beta
or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10)
targeted therapeutics, complete with analysis by
indications, stage of development, mechanism of
action (MoA), route of administration (RoA) and
molecule type. It also reviews key players
involved in Inhibitor of Nuclear Factor Kappa B
Kinase Subunit Beta (Nuclear Factor NF Kappa B
Inhibitor Kinase Beta or I Kappa B Kinase 2 or
IKBKB or EC 2.7.11.10) targeted therapeutics
development with respective active and dormant or
discontinued projects.
4
The report is built using data and information
sourced from proprietary databases,
company/university websites, clinical trial
registries, conferences, SEC filings, investor
presentations and featured press releases from
company/university sites and industry-specific
third party sources.The report provides a
snapshot of the global therapeutic landscape for
Inhibitor of Nuclear Factor Kappa B Kinase
Subunit Beta (Nuclear Factor NF Kappa B Inhibitor
Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC
2.7.11.10)The report reviews Inhibitor of
Nuclear Factor Kappa B Kinase Subunit Beta
(Nuclear Factor NF Kappa B Inhibitor Kinase Beta
or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10)
targeted therapeutics under development by
companies and universities/research institutes
based on information derived from company and
industry-specific sourcesThe report covers
pipeline products based on various stages of
development ranging from pre-registration till
discovery and undisclosed stages
5
The report features descriptive drug profiles for
the pipeline products which includes, product
description, descriptive MoA, RD brief,
licensing and collaboration details other
developmental activitiesThe report reviews key
players involved in Inhibitor of Nuclear Factor
Kappa B Kinase Subunit Beta (Nuclear Factor NF
Kappa B Inhibitor Kinase Beta or I Kappa B Kinase
2 or IKBKB or EC 2.7.11.10) targeted therapeutics
and enlists all their major and minor
projectsThe report assesses Inhibitor of
Nuclear Factor Kappa B Kinase Subunit Beta
(Nuclear Factor NF Kappa B Inhibitor Kinase Beta
or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10)
targeted therapeutics based on mechanism of
action (MoA), route of administration (RoA) and
molecule typeThe report summarizes all the
dormant and discontinued pipeline projectsThe
report reviews latest news and deals related to
Inhibitor of Nuclear Factor Kappa B Kinase
Subunit Beta (Nuclear Factor NF Kappa B Inhibitor
Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC
2.7.11.10) targeted therapeutics
6

Reasons to buyGain strategically significant
competitor information, analysis, and insights to
formulate effective RD strategiesIdentify
emerging players with potentially strong product
portfolio and create effective counter-strategies
to gain competitive advantageIdentify and
understand the targeted therapy areas and
indications for Inhibitor of Nuclear Factor Kappa
B Kinase Subunit Beta (Nuclear Factor NF Kappa B
Inhibitor Kinase Beta or I Kappa B Kinase 2 or
IKBKB or EC 2.7.11.10)Identify the use of drugs
for target identification and drug
repurposingIdentify potential new clients or
partners in the target demographicDevelop
strategic initiatives by understanding the focus
areas of leading companiesPlan mergers and
acquisitions effectively by identifying key
players and it's most promising pipeline
therapeuticsDevise corrective measures for
pipeline projects by understanding Inhibitor of
Nuclear Factor Kappa B Kinase Subunit Beta
(Nuclear Factor NF Kappa B Inhibitor Kinase Beta
or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10)
development landscapeDevelop and design
in-licensing and out-licensing strategies by
identifying prospective partners with the most
attractive projects to enhance and expand
business potential and scope
7
Key Topics covered in the report-Inhibitor
Nuclear FactorInhibitor Nuclear Factor Market
GrowthKappa B Inhibitor Kinase Beta Kappa B
Inhibitor Kinase Beta Market growthInhibitor
Nuclear Factor Market AnalysisInhibitor Nuclear
Factor Market TrendsInhibitor Nuclear Factor
Market StrategyKappa B Inhibitor Kinase Beta
Market AnalysisMarket Report Kappa Kinase
Subunit BetaKappa B Inhibitor Kinase Beta
Market StrategyProducts under Investigation by
Universities
8
For more information on the research report,
refer to below linkhttps//www.kenresearch.com/
healthcare/general-healthcare/inhibitor-of-nuclear
-factor-kappa-b-kinase-subunit-beta-nuclear-factor
pipeline-review/143964-91.htmlRelated
Reports-https//www.kenresearch.com/healthcare/g
eneral-healthcare/home-health-care-residential-nur
sing-care-services-mgr-2017/134577-91.htmlhttps
//www.kenresearch.com/healthcare/general-healthcar
e/qatar-healthcare-market-report/99730-91.htmlht
tps//www.kenresearch.com/healthcare/general-healt
hcare/invacare-corporation-ivc/61939-91.htmlCont
act Ken ResearchAnkur Gupta, Head Marketing
Communicationssales_at_kenresearch.com91-901537824
9    
Write a Comment
User Comments (0)
About PowerShow.com